MedTrace Logo

Inqovi Maintenance Therapy in Myeloid Neoplasms

NCT04980404 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2026-03-30

No results posted yet for this study

Summary

This research is being done to see if the drug Inqov is effective in reducing the chance of myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) relapsing after standard of care stem cell transplant.

* This research study involves the study drug Inqovi, which is a combination of the drugs decitabine and cedazuridine.

Conditions

Interventions

DRUG

Inqovi

Tablet combination of drugs decitabine and cedazuridine, given orally.

Sponsors & Collaborators

  • Taiho Oncology, Inc.

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Zachariah DeFilipp, MD · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-17
Primary Completion
2023-08-24
Completion
2026-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04980404 on ClinicalTrials.gov